TABLE 2.
Age of patients and the onset time of autoimmune hemolytic anemia (AIHA) symptoms following COVID‐19 vaccination according to the gender of individuals
| Observed AIHA | Gender | No. (%) | Age, years mean ± SD median (min − max) | Cases with disease onset after first dose | Onset time after first dose (days) | Cases with disease onset after second dose | Onset time after second dose (days) |
|---|---|---|---|---|---|---|---|
| AIHA development | Men a | 4 (36.4%) |
74.75 ± 7.41 74 (67–84) |
3 (75.0% b ) |
18.0 ± 12.5 c 19.0 (5–30) d |
– | – |
| Women | 7 (64.6%) |
58.57 ± 18.21 53.00 (41–88) |
4 (57.1% b ) |
7.75 ± 4.57 7.0 (3–14) |
3 (42.9% b ) |
45.33 ± 64.94 14.0 (2–120) |
|
| Total | 11 (100.0%) |
64.45 ± 16.79 67.0 (41–88) |
7 (63.6% e ) |
12.14 ± 9.63 7.0 (3–30) |
3 (27.3% e ) |
45.33 ± 64.94 14.0 (2–120) |
|
| AIHA exacerbation | Men | 3 (42.9%) |
69.66 ± 9.45 73.0 (59–77) |
2 (66.7% b ) |
7.0 ± 0.0 7.0 (7.0–7.0) |
1 (33.3% b ) |
1.0 ± 0.0 1 (1.0–1.0) |
| Women f | 4 (57.1%) |
60.50 ± 20.55 65.0 (33–79) |
2 (50.0% b ) |
2.0 ± 0.0 2.0 (2.0–2.0) |
1 (25.0% b ) |
5.0 ± 0.0 5 (5.0–5.0) |
|
| Total | 7 (100.0%) |
64.42 ± 16.27 73.0 (33–79) |
4 (57.1% e ) |
5.33 ± 2.88 7.0 (2.0–7.0) |
2 (28.6% e ) |
3.0 ± 2.82 3 (1.0–5.0) |
In 1 of 4 (25.5%) men, the onset of AIHA symptoms was observed on Day 17 following the booster vaccination.
The percent was calculated within a specified gender.
The onset time expressed as mean ± SD.
The onset time expressed as median (min − max).
The percent was calculated according to the onset time of symptoms.
In 1 of 4 (25.5%) women, the AIHA exacerbation was observed on Day 2 following the booster vaccination.